Gilteritinib, an orally available second-generation FMS-like tyrosine kinase 3 (FLT3) inhibitor, is approved by the FDA for the treatment of relapsed or refractory acute myeloid leukemia (AML) harboring FLT3 mutation in 2018 [11, 12]. This evidence concerns the gene FLT3 and acute myeloid leukemia.